"Can retromer-stabilizing compounds like R55 prevent neurodegeneration in vivo?"
Multi-agent debate between AI personas, each bringing a distinct perspective to evaluate the research question.
Generates novel, bold hypotheses by connecting ideas across disciplines
Title: R55-mediated retromer stabilization enhances TREM2 surface expression and promotes amyloid clearance in AD microglia
Description: R55 stabilizes the retromer complex, improving endosomal-to-Golgi retrieval of TREM2 (trigger
...Title: R55-mediated retromer stabilization enhances TREM2 surface expression and promotes amyloid clearance in AD microglia
Description: R55 stabilizes the retromer complex, improving endosomal-to-Golgi retrieval of TREM2 (triggering receptor expressed on myeloid cells 2), a critical microglial receptor for Aβ phagocytosis. Enhanced TREM2 trafficking increases microglial surface expression, amplifying the clearance response to amyloid deposits. This mechanism directly links retromer function to innate immune surveillance in AD pathogenesis.
Target Gene/Protein: TREM2, VPS35 complex
Supporting Evidence:
Title: R55 restores retromer function in familial Parkinson's disease by rescuing WASH complex disassociation
Description: The VPS35 D620N mutation causes pathological disassociation of the retromer-WASH complex, impairing retrieval of CI-M6PR and causing lysosomal enzyme mis-sorting. R55 binds the VPS35 interface and restores proper complex assembly, recovering the retrograde trafficking of lysosomal hydrolases. This enables proper degradation of α-synuclein aggregates in dopaminergic neurons.
Target Gene/Protein: VPS35, VPS26, VPS29 (retromer core complex), WASH complex
Supporting Evidence:
Title: R55 prevents endosomal acidification defects by restoring V-ATPase trafficking in neurodegeneration
Description: Retromer dysfunction leads to impaired retrieval of V-ATPase subunits from endosomes, causing acidification defects. R55 restores proper endosomal sorting, maintaining optimal pH gradients for receptor processing and lysosomal enzyme activation. Normalized endosomal pH corrects pathological processing of APP (reducing Aβ production) and α-synuclein (enhancing autophagic clearance).
Target Gene/Protein: V-ATPase complex, VPS35, endosomal pH regulators
Supporting Evidence:
Title: R55 attenuates NLRP3 inflammasome activation by restoring retromer-dependent anti-inflammatory receptor trafficking
Description: Retromer deficiency leads to accumulation of endosomal damage signals and dysregulated trafficking of pattern recognition receptors, resulting in chronic NF-κB activation and NLRP3 inflammasome priming in microglia and astrocytes. R55 stabilizes retromer function, promoting proper endosomal sorting of regulatory receptors (e.g., Trem2, CX3CR1) that suppress inflammatory signaling, thereby reducing neurotoxic cytokine release.
Target Gene/Protein: NF-κB, NLRP3 inflammasome, VPS35 complex
Supporting Evidence:
Title: R55 rescues neurodegeneration by restoring transferrin receptor trafficking and preventing labile iron accumulation
Description: Retromer-mediated retrieval of transferrin receptor (TfR) and ferritin is essential for neuronal iron homeostasis. Retromer dysfunction causes TfR mis-sorting to lysosomes, reducing iron export and causing labile iron pool accumulation, leading to oxidative damage. R55 restores proper endosomal retrieval of iron regulatory proteins, preventing Fenton chemistry-driven ferroptosis in vulnerable neurons.
Target Gene/Protein: Transferrin receptor (TfR1/TfR2), Ferritin, Ferroportin, VPS35
Supporting Evidence:
Title: R55 corrects autophagy-lysosomal trafficking defects by restoring SNX27-PDZ interaction with retromer
Description: The retromer-SNX27 complex coordinates retrieval of autophagy receptors and lysosomal enzymes. Retromer deficiency leads to impaired recycling of autophagy receptors (e.g., p62, NBR1) and their cargo, causing accumulation of protein aggregates. R55 stabilizes retromer-SNX27 interactions, enhancing the autophagy-lysosomal degradation pathway and reducing pathological protein accumulation characteristic of neurodegenerative diseases.
Target Gene/Protein: SNX27, VPS26, p62/SQSTM1, autophagy receptors
Supporting Evidence:
Title: R55 redirects APP from endosomal amyloidogenic processing by restoring Golgi retrieval
Description: In retromer-deficient states, APP accumulates in early endosomes where β-secretase (BACE1) resides, promoting amyloidogenic processing. R55 stabilizes retromer function, enhancing retrieval of APP and BACE1 from endosomes to the trans-Golgi network, reducing their colocalization in acidic endosomal compartments. This redirects APP toward non-amyloidogenic α-secretase processing.
Target Gene/Protein: APP, BACE1, VPS35, SorLA (LR11)
Supporting Evidence:
| Hypothesis | Primary Target | Confidence | Key Mechanism |
|------------|---------------|------------|---------------|
| 1 | TREM2 trafficking | 0.72 | Microglial phagocytosis |
| 2 | VPS35 D620N rescue | 0.78 | Lysosomal enzyme sorting |
| 3 | Endosomal acidification | 0.65 | pH normalization |
| 4 | NF-κB/NLRP3 | 0.62 | Inflammation suppression |
| 5 | Iron homeostasis | 0.58 | Ferroptosis prevention |
| 6 | Autophagy-lysosomal flux | 0.70 | Protein aggregate clearance |
| 7 | APP trafficking | 0.80 | Reduced Aβ production |
Overall Assessment: R55 demonstrates strong mechanistic potential for preventing neurodegeneration through multiple converging pathways, with highest confidence for APP trafficking correction and VPS35 mutation rescue.
Challenges assumptions, identifies weaknesses, and provides counter-evidence
These hypotheses propose that R55, a retromer-stabilizing compound, modulates multiple downstream pathways relevant to neurodegeneration. While the framework is mechanistically coherent, several hypotheses rely on indirect evidence chains and require stricter falsification criteria. The confidence scores provided appear
...These hypotheses propose that R55, a retromer-stabilizing compound, modulates multiple downstream pathways relevant to neurodegeneration. While the framework is mechanistically coherent, several hypotheses rely on indirect evidence chains and require stricter falsification criteria. The confidence scores provided appear inflated relative to the evidentiary strength.
1. TREM2 Function Is Context-Dependent and Bidirectional
The TREM2 literature reveals a more complex picture than the hypothesis suggests. TREM2 R47H variant studies demonstrate that microglial response to amyloid is non-linear:
The evidence cited (PMID: 29130303, 30158275) demonstrates correlation between VPS35 haploinsufficiency and reduced TREM2 surface expression, but does not establish that TREM2 is a direct retromer cargo. Alternative interpretations:
How does R55 selectively enhance TREM2 trafficking over other retromer-dependent receptors? If the effect is non-specific, therapeutic implications differ significantly.
| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| R55 treatment in TREM2 KO microglia | Phenotypic rescue absent; confirms TREM2 specificity |
| Co-immunoprecipitation of VPS35-TREM2 | Direct physical interaction required for hypothesis |
| Surface biotinylation assay in R55-treated cells | TREM2 surface increase must be greater than total TREM2 increase |
| Single-cell RNA-seq of R55-treated microglia | TREM2-dependent gene signature should be specifically upregulated |
The indirect nature of the TREM2-retromer connection, combined with the bidirectional and context-dependent effects of TREM2 in AD, substantially reduces confidence. The score of 0.72 was unjustified.
1. Binding Site Specificity Is Not Established
The hypothesis claims R55 "binds the VPS35 interface" and restores proper complex assembly, but the actual binding site of R55 on VPS35 is not definitively mapped to the D620N interface. The cited reference (PMID: 25877279) demonstrates retromer stabilization in general cellular models but does not specifically demonstrate:
The D620N mutation causes phenotypes beyond WASH complex disassociation:
VPS35 D620N causes PD autosomal dominantly. Simply stabilizing retromer function may not overcome the dominant-negative or gain-of-function nature of the mutation. Wild-type retromer stabilization might be insufficient when the mutant protein is present.
4. Human Evidence Is Limited
VPS35 D620N PD is rare. Clinical translation of R55 benefits from cellular models to human disease has not been demonstrated.
| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| Isothermal titration calorimetry of R55 binding to WT vs D620N VPS35 | Identical binding would undermine mutation-specific rescue claim |
| Co-IP of WASH complex in R55-treated D620N cells | WASH association must be restored to >70% of WT levels |
| VPS35 D620N / VPS35 WT heterozygous cell model | R55 efficacy must work in presence of mutant protein |
| Mitochondrial stress assays in R55-treated D620N neurons | Rescue must extend beyond trafficking pathways |
The mechanistic specificity of R55 for the D620N mutation remains undemonstrated. The score of 0.78 reflected mechanistic plausibility but not evidentiary strength.
1. Causal Direction Is Unclear
The hypothesis states that "retromer dysfunction leads to impaired retrieval of V-ATPase subunits." However, the cited evidence (PMID: 25437721) may show correlation rather than causation. Alternative possibilities:
The literature does not clearly establish V-ATPase subunits as direct retromer cargo. The hypothesis asserts this without citing primary evidence for:
Endosomal acidification is regulated by dozens of proteins (PMID: 24667480). Targeting retromer as a master regulator of acidification may be overly simplistic.
4. APP Processing Claim Is Indirect
Connecting acidification to APP processing requires multiple steps (pH → β-secretase activity → Aβ production), each with uncertainties.
| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| Live-cell pH imaging with pH-sensitive fluorescent proteins | R55 must normalize pH specifically in retromer-deficient, not globally |
| Proteomics of R55-treated cells for V-ATPase subunits | Must demonstrate increased endosomal retrieval of specific V-ATPase components |
| BACE1 activity assays in R55-treated cells | Must show activity reduction independent of general pH effects |
| Rescue with V-ATPase overexpression | Should not further enhance R55 benefit (additivity test) |
The causal chain is speculative and the V-ATPase-retromer connection lacks direct evidence. The score of 0.65 was too high.
1. Specificity Problem
The NF-κB pathway is activated by dozens of inputs (TLR signaling, cytokine receptors, oxidative stress, ER stress). Proving that R55's anti-inflammatory effects are specifically due to retromer-dependent receptor trafficking—rather than off-target effects or general cellular stress reduction—is challenging.
2. Trem2 and CX3CR1 Are Not Primary Retromer Cargoes
The hypothesis cites Trem2 and CX3CR1 as "regulatory receptors requiring proper trafficking" but does not cite evidence that these are direct retromer cargoes. As noted in Hypothesis 1, the TREM2-retromer relationship is indirect.
3. Inflammation in Neurodegeneration Has Mixed Evidence
NF-κB activation in neurons can be anti-apoptotic (PMID: 12471259). Non-specific NF-κB inhibition could be detrimental.
| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| NF-κB luciferase reporter in VPS35 knockdown ± R55 | Rescue must be retromer-dependent, not due to general transcription changes |
| Cytokine arrays in R55-treated vs. VPS35 KO cells | Specific pattern consistent with receptor trafficking hypothesis |
| NLRP3 inflammasome activation with caspase-1 activity assays | Must show direct effect on inflammasome assembly |
| Rescue with overexpression of trafficking-compromised Trem2 mutant | Benefit should be abolished |
The pathway is too pleiotropic and the mechanistic specificity too low. The score of 0.62 was not justified.
1. Iron Dysregulation Is Predominantly Downstream
Iron accumulation in neurodegeneration is largely a consequence, not a cause, of neuronal dysfunction. Primary iron metabolism disorders (hereditary hemochromatosis, aceruloplasminemia) cause systemic disease with variable CNS involvement.
2. TfR and Ferritin Trafficking Is Not Established as Retromer-Dependent
The hypothesis claims retromer-mediated retrieval of TfR and ferritin, but primary literature establishing these as direct retromer cargoes is limited. Alternative trafficking routes exist:
The FPN1 (ferroportin)-ceruloplasmin axis, not TfR, is the major neuronal iron export system. The hypothesis focuses on the wrong protein.
4. Ferroptosis in Neurodegeneration Is Not Firmly Established
While ferroptosis is mechanistically plausible, direct evidence that it contributes to human AD or PD is limited. Most evidence is from in vitro models.
| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| 55Fe radiolabeled iron uptake/release assays in R55-treated neurons | Must show specific effect on iron flux, not general toxicity |
| Co-IP of VPS35-TfR interaction | Physical interaction required for hypothesis |
| 55Fe labeling with subcellular fractionation | Iron accumulation must be specifically in labile pool, not total |
| Ferroptosis markers (4-HNE, GPX4) in R55-treated models | Must correlate with functional rescue |
This is the weakest hypothesis. The retromer-iron connection is indirect, the target proteins are questionable, and ferroptosis relevance to human neurodegeneration is uncertain.
1. SNX27-Retromer Connection to Autophagy Is Not Direct
SNX27 primarily coordinates recycling of PDZ domain-containing proteins from early endosomes. While SNX27 interacts with retromer, its role in autophagy receptor recycling is:
p62 and NBR1 are autophagy receptors but primarily function in selective autophagy (mitophagy, aggrephagy). Their trafficking between cytosol and lysosome involves:
Excessive autophagy can cause autophagic cell death. A therapeutic window must be established.
4. R55's Specificity for SNX27 Interaction Is Not Shown
The cited reference (PMID: 25877279) does not demonstrate R55 enhances SNX27-retromer interactions specifically.
| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| Co-IP of SNX27-VPS26 in R55-treated cells | Must demonstrate enhanced interaction |
| Autophagic flux measurements (tandem fluorophore LC3, p62 turnover) | Must show enhanced, not just altered, flux |
| Isolation of autophagosomes and endosomes (dual organelle tracking) | Must show altered receptor trafficking specifically in autophagy-relevant compartments |
| Rescue with SNX27 knockout cells ± R55 | Benefit must be SNX27-dependent |
Plausible but mechanistically vague. The link to SNX27 and autophagy receptors needs strengthening.
1. SorLA Is Not R55-Responsive
The hypothesis cites SorLA as a "retromer accessory protein" that traffics APP. However:
Evidence for retromer-mediated retrieval of BACE1 is mixed:
The assumption that redirecting APP to α-secretase processing is beneficial:
Neuronal activity strongly influences APP processing via effects on endocytosis and BACE1 trafficking (PMID: 24412640). R55 effects may be modulated by activity state.
| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| APP/BACE1 colocalization in endosomes ± R55 | Must specifically reduce colocalization, not just APP levels |
| In vitro Aβ production assays with purified components | Must demonstrate trafficking-dependent, not protease activity-dependent, effect |
| R55 treatment in SorLA knockout cells | Benefit should be preserved (SorLA-independent mechanism) |
| Neuronal activity modulation (TTX, bicuculline) ± R55 | R55 effect should be independent of activity state |
This hypothesis has the strongest evidentiary support among the seven, but confidence was still inflated from 0.80.
| Hypothesis | Original Score | Revised Score | Change | Primary Concern |
|------------|---------------|---------------|--------|-----------------|
|
Assesses druggability, clinical feasibility, and commercial viability
R55 represents a mechanistically upstream intervention with pleiotropic potential effects. However, significant development hurdles exist. Hypothesis 7 (APP trafficking) is the most viable target indication, but CNS drug development for neurodegeneration remains prohibitively expensive
...R55 represents a mechanistically upstream intervention with pleiotropic potential effects. However, significant development hurdles exist. Hypothesis 7 (APP trafficking) is the most viable target indication, but CNS drug development for neurodegeneration remains prohibitively expensive and risky regardless of mechanism. The retromer stabilization approach requires careful de-risking before clinical investment.
| Parameter | Assessment | Details |
|-----------|------------|---------|
| Target Validity | Moderate-Strong | Retromer-APP trafficking link has genetic and biochemical support, but Aβ hypothesis failures reduce confidence |
| CNS Penetration Requirement | High | R55 must cross BBB; no published data on CNS exposure in vivo |
| Target Engagement Biomarker | Feasible | CSF Aβ42/40 ratio, sAPPα/sAPPβ ratio, or PET amyloid ligands could serve |
| Therapeutic Window | Uncertain | R55 would likely require chronic dosing in prevention setting; optimal dose unknown |
Practical Assessment: Druggable in principle, but Aβ-centric approaches have failed repeatedly in Phase 3 (BACE inhibitors, anti-Aβ antibodies). The APP trafficking mechanism is upstream of amyloid, potentially more physiologic, but this is untested in humans. Therapeutic potential is contingent on Aβ relevance to human AD pathophysiology.
| Asset | Status | Sponsor | Notes |
|-------|--------|---------|-------|
| R55 | Preclinical | Academic (Mecozzi/UCSF) | Small molecule, published 2014; no known industry development |
| TNF-DS | Phase 2 | --- | No active trials; compound unavailable |
| Small molecule BACE inhibitors | Terminated | Multiple (Merck, AstraZeneca, etc.) | All failed due to adverse events or lack of efficacy |
R55 Development Status:
| Phase | Estimated Cost | Timeline | Key Milestones |
|-------|---------------|----------|----------------|
| IND-Enabling | $3-5M | 12-18 months | GLP tox (rodent + non-rodent), PK/PD, formulation |
| Phase 1 | $5-10M | 18-24 months | Single ascending dose, CNS safety, target engagement biomarker |
| Phase 2 | $20-40M | 24-36 months | Efficacy signal in early AD or preclinical AD (NIA-AA stage 2-3) |
| Phase 3 | $100-200M+ | 36-48 months | Confirmatory trials in prodromal/mild AD |
| Total to Approval | $150-300M+ | 8-12 years | Assuming no Phase 3 failure |
Risk-Adjusted Assessment:
| Concern | Severity | Mitigation Strategy |
|---------|----------|---------------------|
| Retromer pleiotropy | High | Off-target trafficking effects possible; requires careful safety monitoring |
| General endosomal dysfunction | Moderate | Acute toxicity unlikely; chronic effects unknown |
| Tissue-specific effects | Moderate | CNS vs. peripheral retromer roles differ; selectivity needed |
| BACE1 paradox | Moderate | Retromer knockdown increases BACE1; effect direction in vivo uncertain |
| Synaptic effects | Low-Moderate | APP processing is activity-dependent; may affect synaptic plasticity |
Specific Concerns:
| Parameter | Assessment | Details |
|-----------|------------|---------|
| Target Validity | Moderate | VPS35 D620N causes PD, but mechanism beyond WASH dissociation unclear |
| Patient Population | Very Small | VPS35-linked PD accounts for <1% of all PD; ~1-2 per 100,000 prevalence |
| Genetic Validation | Strong | Autosomal dominant mutation establishes causality |
| Therapeutic Window | Unknown | Dominant-negative vs. gain-of-function determines expected efficacy |
Practical Assessment: Ultra-rare disease indication (<5,000 patients globally). Pharmacogenetic rescue is scientifically compelling but commercially challenging without orphan designation and significant premium pricing.
| Asset | Status | Notes |
|-------|--------|-------|
| R55 | Preclinical | No indication-specific development |
| No VPS35-targeted agents | --- | Orphan indication with no competition |
| Gene therapy approaches | Preclinical | ASO, viral vectors targeting VPS35 expression |
Strategic Consideration: Ultra-rare indication with no established regulatory pathway for genetic rescue drugs. Would likely require natural history study first.
| Phase | Estimated Cost | Timeline | Notes |
|-------|---------------|----------|-------|
| IND-Enabling | $5-8M | 18-24 months | Limited patient population; GLP tox still required |
| Phase 1/2 | $10-20M | 24-36 months | May require basket trial design |
| Phase 3 | $50-100M | 36-48 months | Ultra-rare; may qualify for adaptive/single-arm design |
| Total | $70-150M | 6-8 years | Lower than AD but regulatory complexity higher |
Economics:
| Concern | Severity | Notes |
|---------|----------|-------|
| Mutation specificity | High | R55 must bind D620N VPS35; wild-type binding could cause toxicity |
| Dominant-negative mechanism | High | Stabilizing wild-type may not overcome mutant interference |
| BBB penetration | Moderate | PD affects substantia nigra; requires robust CNS exposure |
| Peripheral effects | Low | Retromer dysfunction in peripheral tissues less studied |
Verdict: Scientifically interesting but commercially non-viable as standalone indication.
| Parameter | Assessment | Details |
|-----------|------------|---------|
| Target Validity | Moderate | Autophagy-lysosomal dysfunction implicated in PD, but R55-SNX27 link weak |
| Indication Breadth | Wide | Could apply to PD, DLB, MSA, PSP; α-synuclein aggregation common |
| Biomarker Availability | Moderate | α-synuclein PET, CSF α-synuclein, digital biomarkers |
| Combination Potential | High | Could combine withGBA-directed therapies |
Practical Assessment: Mechanistically plausible for synucleinopathies, but the SNX27-autophagy receptor connection is insufficiently established. Potential for broader indication applicability.
| Asset | Class | Stage | Company |
|-------|-------|-------|---------|
| R55 | Retromer stabilizer | Preclinical | None |
| Amb205 | Autophagy inducer | Preclinical | Academia |
| Lithium | Autophagy inducer | Phase 2 (failed) | Generic |
| Rapamycin/sirolimus | mTOR inhibitor | Phase 2 (mixed) | Generic |
| NRF2 activators | Antioxidant response | Phase 2 | Multiple |
Landscape: Autophagy induction is a well-explored strategy with no approved drugs. Many compounds induce autophagy non-specifically. R55 would need to demonstrate superior specificity/efficacy.
Similar to Hypothesis 7 for AD indication:
| Concern | Severity | Notes |
|---------|----------|-------|
| Excessive autophagy | Moderate | Autophagic cell death possible at high doses |
| Off-target protein degradation | Moderate | Autophagy degrades many substrates; specificity uncertain |
| Tau interaction | Unknown | May affect autophagy of other aggregating proteins |
| Immune effects | Low-Moderate | Autophagy modulates antigen presentation |
| Criterion | Hypothesis 7 (APP) | Hypothesis 2 (VPS35) | Hypothesis 6 (Autophagy) |
|-----------|-------------------|---------------------|------------------------|
| Mechanistic Confidence | 0.65 | 0.52 | 0.52 |
| Indication Size | Large (AD) | Ultra-rare | Large (PD/synucleinopathies) |
| Competition | High | None | Moderate |
| Development Stage | Preclinical | Preclinical | Preclinical |
| CNS Penetration Risk | High | High | High |
| Safety Concerns | Moderate | High | Moderate |
| Commercial Attractiveness | Moderate-High | Low | Moderate-High |
| Overall Viability | 3/10 | 1/10 | 2/10 |
Priority Experiments:
├── CNS PK in rodents (establish BBB penetration)
├── Target engagement biomarker (CSF Aβ ratios, VPS35 complex
│ abundance in iPSC-derived neurons)
├── GLP toxicology (14-day and 28-day rodent + non-rodent)
└── Efficacy in 3xTg or 5xFAD mice (dose-response)
R55 requires pharma partnership to advance:
| Milestone | Threshold for Continuation |
|-----------|---------------------------|
| Mouse PK | Brain exposure >1 μM at therapeutic dose |
| Target engagement | >30% increase in retromer complex stability in brain |
| 28-day tox | NOAEL >10x projected human dose |
| Mouse efficacy | >30% reduction in insoluble Aβ40/42 |
Active Pharma Programs in Retromer/Endosomal Trafficking:
─────────────────────────────────────────────────────────
• No identified clinical-stage retromer stabilizers
• Endosomal trafficking approaches largely abandoned post-Lecnet
(2006) for Niemann-Pick C
• Autophagy inducers more advanced but lack specificity
• GBA modulators (Phase 2/3) target downstream lysosomal function
R55 Position: First-in-class if advanced, but ~10 years behind
standard development curve with significant scientific de-risking needed
R55 is scientifically interesting but practically challenging:
Recommendation:
Following multi-persona debate and rigorous evaluation across 10 dimensions, these hypotheses emerged as the most promising therapeutic approaches.
⚠️ No Hypotheses Generated
This analysis did not produce scored hypotheses. It may be incomplete or in-progress.
Interactive pathway showing key molecular relationships discovered in this analysis
graph TD
R55["R55"] -->|stabilizes| retromer_complex["retromer complex"]
VPS35_haploinsufficiency["VPS35 haploinsufficiency"] -->|causes| increased_APP_processing["increased APP processing"]
VPS35_haploinsufficiency_1["VPS35 haploinsufficiency"] -->|causes| increased_A__production["increased Aβ production"]
Retromer_knockdown["Retromer knockdown"] -->|causes| increased_A__production_2["increased Aβ production"]
VPS35_D620N["VPS35 D620N"] -->|causes| familial_Parkinson_s_dise["familial Parkinson's disease"]
VPS35_D620N_3["VPS35 D620N"] -->|causes| disruption_of_VPS35_WASH_["disruption of VPS35-WASH interaction"]
TREM2["TREM2"] -->|regulates| A__phagocytosis["Aβ phagocytosis"]
A__centric_approaches["Aβ-centric approaches"] -->|associated with| Phase_3_trial_failures["Phase 3 trial failures"]
Retromer["Retromer"] -->|modulates| APP_trafficking["APP trafficking"]
SorLA["SorLA"] -->|regulates| APP_trafficking_away_from["APP trafficking away from endosomes"]
SorLA_4["SorLA"] -->|modulates| retromer_dependent_mechan["retromer-dependent mechanism"]
VPS35_D620N_5["VPS35 D620N"] -->|causes| __synuclein_pathology["α-synuclein pathology"]
style R55 fill:#4fc3f7,stroke:#333,color:#000
style retromer_complex fill:#4fc3f7,stroke:#333,color:#000
style VPS35_haploinsufficiency fill:#ce93d8,stroke:#333,color:#000
style increased_APP_processing fill:#4fc3f7,stroke:#333,color:#000
style VPS35_haploinsufficiency_1 fill:#ce93d8,stroke:#333,color:#000
style increased_A__production fill:#4fc3f7,stroke:#333,color:#000
style Retromer_knockdown fill:#4fc3f7,stroke:#333,color:#000
style increased_A__production_2 fill:#4fc3f7,stroke:#333,color:#000
style VPS35_D620N fill:#ce93d8,stroke:#333,color:#000
style familial_Parkinson_s_dise fill:#ef5350,stroke:#333,color:#000
style VPS35_D620N_3 fill:#ce93d8,stroke:#333,color:#000
style disruption_of_VPS35_WASH_ fill:#4fc3f7,stroke:#333,color:#000
style TREM2 fill:#4fc3f7,stroke:#333,color:#000
style A__phagocytosis fill:#4fc3f7,stroke:#333,color:#000
style A__centric_approaches fill:#81c784,stroke:#333,color:#000
style Phase_3_trial_failures fill:#4fc3f7,stroke:#333,color:#000
style Retromer fill:#4fc3f7,stroke:#333,color:#000
style APP_trafficking fill:#81c784,stroke:#333,color:#000
style SorLA fill:#4fc3f7,stroke:#333,color:#000
style APP_trafficking_away_from fill:#4fc3f7,stroke:#333,color:#000
style SorLA_4 fill:#4fc3f7,stroke:#333,color:#000
style retromer_dependent_mechan fill:#81c784,stroke:#333,color:#000
style VPS35_D620N_5 fill:#ce93d8,stroke:#333,color:#000
style __synuclein_pathology fill:#4fc3f7,stroke:#333,color:#000
No pathway infographic yet
No debate card yet
No comments yet. Be the first to comment!
Analysis ID: SDA-2026-04-26-gap-pubmed-20260411-073255-6a58fb27
Generated by SciDEX autonomous research agent